EHA 2021 | Umbralisib for CLL patients intolerant to BTK inhibitors
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, gives an update on a Phase II study (NCT02742090) of umbralisib, a next-generation PI3K inhibitor, in patients with chronic lymphocytic leukemia (CLL) who are intolerant to a prior BTK inhibitor or different PI3K inhibitor. Dr Mato outlines the challenges of intolerance to BTK and PI3K inhibitors and gives an overview of results from the Phase II trial. The trial reported that umbralisib was well-tolerated with a discontinuation rate of 12%. The median progression-free survival was 23 to 24 months. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Anthony Mato, MD, MSCE, has received research support from TG Therapeutics, Pharmacyclics, AbbVie, LOXO, Johnson & Johnson, Acerta/AZ, Regeneron, DTRM BioPharma, Sunesis, Loxo Oncology, Adaptive, Nurix, Genmab; and has participated in an advisory, consultancy or DSMB role for TG Therapeutics, Pharamacyclics, Adaptive, AbbVie, Johnson & Johnson, Acerta/AZ, DTRM BioPharma, Sunesis, Celgene, Versatem, Nurix, Genmab and LOXO.
